Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Protein Tyrosine Kinase/RTK

Items 81-90 of 128

Page
per page
  1. Nilotinib hydrochloride
    C6509 Nilotinib hydrochloride
    Summary: An orally active Bcr-Abl tyrosine kinase inhibitor for chronic myeloid leukemia (CML)
      ≥100 mg/mL
  2. Chloropyramine hydrochloride
    C6401 Chloropyramine hydrochloride
    Summary: A histamine H1 receptor antagonist with antiallergic and antitumor applications
      ≥18.95 mg/mL
  3. lenvatinib Mesylate
    C6375 lenvatinib Mesylate
     1 Citation
    Summary: An orally active multi-target tyrosine kinase inhibitor of VEGFR2, VEGFR3, FGFR, and PDGFR for angiogenesis and hepatocellular carcinoma
      ≥12.53 mg/mL
  4. Nintedanib esylate
    C6370 Nintedanib esylate
    Summary: A triple tyrosine kinase inhibitor of VEGFR, FGFR, and PDGFR
      ≥26.15 mg/mL
  5. Trastuzumab
    B8790 Trastuzumab
    Summary: A humanized monoclonal antibody for the treatment of HER2-positive breast cancer and gastric cancer
  6. Deucravacitinib
    B8781 Deucravacitinib
    Summary: An orally active TYK2 inhibitor for the treatment of moderate-to-severe plaque psoriasis
      ≥14.08 mg/mL
  7. BLU-554
    B8391 BLU-554
    Summary: A highly selective oral FGFR4 inhibitor for the treatment of hepatocellular carcinoma
      ≥50.4 mg/mL
  8. Erdafitinib
    B8387 Erdafitinib
    Summary: An orally available pan-FGFR inhibitor with potential antitumor activity
  9. Harmine
    B8316 Harmine
    Summary: Harmine
      insoluble in H2O; ≥33 mg/mL
  10. Pexidartinib (PLX3397)
    B5854 Pexidartinib (PLX3397)
     7 Citation
    Target: FLT3|c-Kit|CSF1R
    Summary: A multi-targeted receptor tyrosine kinase inhibitor; A CSF-1R inhibitor
      insoluble in EtOH; insoluble in H2O; ≥20.9 mg/mL

Items 81-90 of 128

Page
per page
Relate Categories
Category
  1. FGFR3item